On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor Inhibitors

Abstract Introduction There is limited prior literature comparing long-term treatment persistence between guselkumab and subcutaneous (SC) tumor necrosis factor inhibitors (TNFi) in biologic-naïve and biologic-experienced patients with active psoriatic arthritis (PsA). This study compared on-label p...

Полное описание

Библиографические подробности

Главные авторы:	Philip J. Mease, Jessica A. Walsh, Timothy P. Fitzgerald, Soumya D. Chakravarty, Elizabeth Adamson, Bruno Emond, Carmine Rossi, Samuel Schwartzbein, Kana Yokoji, Yuxi Wang, Patrick Lefebvre, Dominic Pilon, Shikha Singla, Joseph F. Merola
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Adis, Springer Healthcare 2025-11-01
Серии:	Rheumatology and Therapy
Предметы:	Biologic-experienced Biologic-naïve Guselkumab Psoriatic arthritis Subcutaneous tumor necrosis factor inhibitor Treatment persistence
Online-ссылка:	https://doi.org/10.1007/s40744-025-00804-3
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!